Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

NCT02378389 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Gastric Cancer

Interventions

DRUG: Pyrotinib/Pyrotinib with Docetaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.